IP Verse

Engineered Virus - EP3400291

The patent EP3400291 was granted to Replimune on Feb 28, 2024. The application was originally filed on Jan 9, 2017 under application number EP17700385A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3400291

REPLIMUNE
Application Number
EP17700385A
Filing Date
Jan 9, 2017
Status
Patent Maintained As Amended
Jan 26, 2024
Grant Date
Feb 28, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANAug 4, 2021POTTER CLARKSONADMISSIBLE
COHAUSZ & FLORACK PATENT UND RECHTSANWALTE PARTNERSCHAFTSGESELLSCHAFT MBBAug 3, 2021REGIMBEAUADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2011044953
DESCRIPTIONUS2015283234
DESCRIPTIONWO2007123737
DESCRIPTIONWO2014066532
INTERNATIONAL-SEARCH-REPORTWO2006002394
OPPOSITIONEP3169341
OPPOSITIONWO0153505
OPPOSITIONWO2016008976
OPPOSITIONWO2017118866

Non-Patent Literature (NPL) Citations (29) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CHOU ET AL., SCIENCE, (1990), vol. 250, pages 1262 - 1266-
DESCRIPTION- LIU ET AL., GENE THERAPY, (2003), vol. 10, pages 292 - 303-
DESCRIPTION- MACLEAN ET AL., J. GEN. VIROL., (1991), vol. 72, pages 631 - 639-
EXAMINATION- Angelica Loskog, "Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles", Viruses, (20151106), vol. 7, no. 11, doi:10.3390/v7112899, pages 5780 - 5791, XP055461039
INTERNATIONAL-SEARCH-REPORT- Geoffrey Thomas Gibney, "Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. | 2014 ASCO Annual Meeting | Abstracts | Meeting Library", (20040501), URL: http://meetinglibrary.asco.org/content/127143-144, (20170222), XP055348796 [A] 1-18,20-22,24-48 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- Piasecki et al., "Talilmogene laherparepvec increases the anti-tumor efficacy of the anti-PD-1 immune checkpoint blockade.", (20150419), URL: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3682&sKey=ebc7290a-af22-4fa6-9436-c276011fb181&cKey=b61c1150-5517-456b-acd3-2f8048807587&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424, (20170222), XP055348530 [X] 1-18,20-22,24-48 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- LIU B L ET AL, "ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties", GENE THERAPY, NATURE PUBLISHING GROUP, GB, (20030201), vol. 10, no. 4, doi:10.1038/SJ.GT.3301885, ISSN 0969-7128, pages 292 - 303, XP002313120 [X] 1-18,20-22,24-48 * page 299, column l * * page 295 * * figure 2 *
INTERNATIONAL-SEARCH-REPORT- YAN WEN ET AL, "Developing novel oncolytic adenoviruses through bioselection", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, (20030201), vol. 77, no. 4, doi:10.1128/JVI.77.4.2640-2650.2003, ISSN 0022-538X, pages 2640 - 2650, XP002394479 [A] 1-18,20-22,24-48 * abstract * * page 2642, column r, paragraph 2 full *
INTERNATIONAL-SEARCH-REPORT- G. R. SIMPSON, "Combination of a Fusogenic Glycoprotein, Prodrug Activation, and Oncolytic Herpes Simplex Virus for Enhanced Local Tumor Control", CANCER RESEARCH, (20060501), vol. 66, no. 9, doi:10.1158/0008-5472.CAN-05-4352, ISSN 0008-5472, pages 4835 - 4842, XP055113042 [X] 1-18,20-22,24-48 * abstract * * page 4835, column r, paragraph l *
INTERNATIONAL-SEARCH-REPORT- N. N. SENZER ET AL, "Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma", JOURNAL OF CLINICAL ONCOLOGY, (20091102), vol. 27, no. 34, doi:10.1200/JCO.2009.24.3675, ISSN 0732-183X, pages 5763 - 5771, XP055207592 [X] 1-18,20-22,24-48 * page 5763, column r *
INTERNATIONAL-SEARCH-REPORT- NICOLAS SOKOLOWSKI ET AL, "Oncolytic virotherapy using herpes simplex virus: how far have we come?", ONCOLYTIC VIROTHERAPY, (20151101), doi:10.2147/OV.S66086, page 207, XP055347641 [X] 1-18,20-22,24-48 * tables 1-3 *
OPPOSITION- Jean-François Fonteneau et al (2016) Oncolytic immunotherapy: The new clinical outbreak, Oncolmmunoloqy, 5:1,e1066961-
OPPOSITION- K-J Choi, S-N Zhang1’2’5, I-K Choi3’5, J-S Kim1 And C-O Yun4, "Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12and GM-CSF", Gene Therapy, (20120101), vol. 19, pages 711 - 723, XP055904334-
OPPOSITION- LEE et al., "Oncolytic potential of E1B 55 kDa-deleted YKL-1 recombinant adenovirus: correlation with p53 functional status", Int J Cancer, (20000000), vol. 88, doi:10.1002/1097-0215(20001101)88:3<454::AID-IJC19>3.0.CO;2-T, pages 454 - 463, XP002365923
OPPOSITION- SUMIMOTO H et al., "GM- CSF and B7-1 ( CD 80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice", Int J Cancer, (19971114), vol. 73, no. 4, pages 556 - 61, XP071278109
OPPOSITION- LI B et al., "Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1 BB mAb", Clin Immunol, (20071000), vol. 125, no. 1, doi:10.1016/j.clim.2007.07.005, pages 76 - 87, XP022240713
OPPOSITION- GAO Y, ET AL, "Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors", Cancer Gene Therapy, Nature Publishing Group US, New York, New York, (20090101), vol. 16, no. 1, doi:10.1038/CGT.2008.55, ISSN 0929-1903, pages 44 - 52, XP002606262
OPPOSITION- T Du, Shi G, Li Y M, Zhang J F, Tian H W, Wei Y Q, Deng H, Yu D C, "Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers", Cancer Gene Therapy, Appleton & Lange, (20140801), vol. 21, no. 8, doi:10.1038/cgt.2014.34, ISSN 09291903, pages 340 - 348, XP055214039
OPPOSITION- KAUFMAN, H. et al., "Oncolytic viruses: a new class of immunotherapy drugs", Nat Rev Drug Discov, (20150000), vol. 14, doi:10.1038/nrd4663, pages 642 - 662, XP037065528
OPPOSITION- YO YT et al., "Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine", Cancer Gene Ther., (20071100), vol. 14, no. 11, doi:10.1038/sj.cgt.7701081, pages 904 - 17, XP055577263
OPPOSITION- Z-B Hu, C-T Wu, H Wang, Q-W Zhang, L Wang, R-L Wang, Z-Z Lu, L-S Wang, "A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes", Cancer Gene Therapy, Appleton & Lange, (20080301), vol. 15, no. 3, doi:10.1038/sj.cgt.7701105, ISSN 09291903, pages 173 - 182, XP055017566
OPPOSITION- CHOI K-J ET AL, "Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.", Gene Therapy, Nature Publishing Group, London, GB, GB , (20060701), vol. 13, no. 13, doi:10.1038/sj.gt.3302759, ISSN 0969-7128, pages 1010 - 1020, XP002571567
OPPOSITION- AHLERS JD et al., "A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL -13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD 40L", Proc Natl Acad Sci U S A., (20021001), vol. 99, no. 20, doi:10.1073/pnas.192251199, pages 13020 - 5, XP002489213
OPPOSITION- HURWITZ AA et al., "CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma", Proc Natl Acad Sci U S A., (19980818), vol. 95, no. 17, doi:10.1073/pnas.95.17.10067, pages 10067 - 71, XP002133809
OPPOSITION- Daria Capece, Daniela Verzella, Mariafausta Fischietti, Francesca Zazzeroni, Edoardo Alesse, "Targeting Costimulatory Molecules to Improve Antitumor Immunity", Journal of Biomedicine and Biotechnology, (20120101), vol. 179, no. 11, doi:10.1155/2012/926321, ISSN 11107243, pages 7365 - 17, XP055100761
OPPOSITION- LI B et al., "Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors", Clin Cancer Res., (20090301), vol. 15, no. 5, doi:10.1158/1078-0432.CCR-08-1825, pages 1623 - 34, XP055166457
OPPOSITION- ASSAL A et al., "Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD- 1", Immunotherapy, (20150000), vol. 7, no. 11, doi:10.2217/imt.15.78, pages 1169 - 86, XP055406835
OPPOSITION- Gri Giorgia, Gallo Elena, Di Carlo Emma, Musiani Piero, Colombo Mario P., "OX40 Ligand-Transduced Tumor Cell Vaccine Synergizes with GM-CSF and Requires CD40-Apc Signaling to Boost the Host T Cell Antitumor Response", The Journal of Immunology, Williams & Wilkins Co., US, US , (20030101), vol. 170, no. 1, doi:10.4049/jimmunol.170.1.99, ISSN 0022-1767, pages 99 - 106, XP055920414
OPPOSITION- MURATA S et al., "OX40 costimulation synergizes with GM-CSF whole- cell vaccination to overcome established CD 8+ T cell tolerance to an endogenous tumor antigen", J Immunol., (20060115), vol. 176, no. 2, doi:10.4049/jimmunol.176.2.974, pages 974 - 83, XP055149674

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents